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ABSTRACT Aspartylglycosaminuria is an inherited lyso-
somal storage disease caused by deficiency of glycoasparagi-
nase (EC 3.5.1.26) and occurs with higher frequency among
Finns than other populations. We have purified human gly-
coasparaginase and determined about 90% of the amino acid
sequence of its light subunit and >70% of that of its heavy
subunit by Edman degradation and mass spectrometry. Addi-
tional sequence data were obtained from the cloning and
subsequent nucleotide analysis of a cDNA corresponding to the
normal human glycoasparaginase gene. The enzyme is encoded
by a single mRNA as a single polypeptide that is posttransla-
tionally processed to generate the subunits and is glycosylated.
After preparing first-strand cDNA from leukocyte and fibro-
blast total RNA, we used the polymerase chain reaction to
amplify the glycoasparaginase cDNA of eight Finnish aspar-
tylglycosaminuria patients. We demonstrate that the Finnish
patients' mRNA sequence differed from the normal sequence
by two single-base changes six nucleotides apart from one
another in the heavy chain of glycoasparaginase. The first
change resulted in the replacement of arginine by glutamine
(R161Q), whereas the second change resulted in a cysteine to
serine substitution (C163S). Both mutations resulted in novel
restriction endonuclease sites and were present in all eight
Finnish aspartylglycosaminuria patients originating from dif-
ferent pedigrees, but they were absent from Finnish and
non-Finnish controls and a non-Finnish case of aspartylgly-
cosaminuria. These results indicate molecular homogeneity in
aspartylglycosaminuria alleles in the Finnish population.
of an active glycoasparaginase enzyme from these has not
been described.
The genetic structure of the Finnish population is unique in
that 20 or more monogenic disorders are more common in
that population than in other Caucasian populations (5).
Inborn errors commonly occurring in other populations, such
as phenylketonuria, cystic fibrosis, and galactosemia, are
almost nonexistent in Finland (6). Aspartylglycosaminuria is
one ofthose "Finnish diseases," and its frequency in eastern
and northern Finland has been estimated as 1:4000-1:7000 (7,
8). This is the highest frequency described for any glycopro-
teinosis in any population and is comparable to the incidence
figures of the most common lysosomal storage diseases,
Gaucher disease type 1 (9) and Tay-Sachs disease (10) among
Ashkenazi Jews. Although isolated cases of this disorder
presenting with mental retardation, dysplasia, cardiac val-
vular involvement, and angiokeratoma have been reported
elsewhere in the world (1), a phenotype with mental retar-
dation, speech disorder, motor clumsiness, coarse face, and
osteochondrotic changes as the most prominent clinical find-
ings is consistently found among the Finnish aspartylgly-
cosaminuria patients (8). The molecular defect(s) underlying
the disease is unknown. In this study, we present evidence
for two single-base changes in the heavy chain of glycoas-
paraginase found in aspartylglycosaminuria patients of Finn-
ish descent.** Both mutations were absent from controls of
Finnish and non-Finnish origin as well as one aspartylgly-
cosaminuria case of non-Finnish origin.
Glycoasparaginase [N4-(13-N-acetylglucosaminyl)-L-aspara-
ginase, EC 3.5.1.26] is a lysosomal enzyme that catalyzes the
hydrolysis of the linkage between N-acetylglucosamine and
asparagine, the attachment point of N-glycosidic carbohy-
drate chains to the protein chain. The deficient activity of
glycoasparaginase in humans causes an autosomal recessive,
lysosomal storage disease, aspartylglycosaminuria (McKu-
sick 20840), characterized by serious psychomotor retarda-
tion and accumulation of large amounts of aspartylglu-
cosamine in body fluids and tissues (1). To study the bio-
chemistry and cell biology of glycoasparaginase, we have
isolated the enzyme from human leukocytes (2). We have
shown that the native enzyme is an 88-kDa glycoprotein that
has a heterotetrameric structure composed of two 25-kDa
heavy chains and two 19-kDa light chains that by themselves
are enzymatically inactive. It has been suggested that human
glycoasparaginase is encoded as a single polypeptide that is
posttranslationally processed to generate the subunits (3). At
least two different cDNA clones for human glycoasparagi-
nase have been reported (3, 4), but as of yet, the expression
MATERIALS AND METHODS
Human Leukocyte Glycoasparagnase. Glycoasparaginase
was purified 4600-fold from human leukocytes (2). The heavy
(25-kDa) and light (19-kDa) subunits of the native 88-kDa
enzyme were isolated by reverse-phase HPLC. Peptides
produced from these subunits by cyanogen bromide cleavage
and digestion with chymotrypsin, trypsin,. or endoprotein-
ases Glu-C, Lys-C, and Asp-N, respectively, were isolated
by reverse-phase HPLC and sequenced by automated Edman
degradation (Applied Biosystems 477A protein sequencer
and 120A phenylthiohydantoin analyzer) or mass spectrom-
etry (Finnigan MAT TSQ70 triple quadrupole mass spec-
trometer) (11, 12).
Designation of Aspartyiglycosaminuria Patients and Normal
Controls. Total RNA was isolated from leukocytes offive and
from fibroblast cell lines of another three Finnish aspartyl-
glycosaminuria patients from different pedigrees. The pa-
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tients had typical clinical manifestations of aspartylgly-
cosaminuria. They excreted large amounts of aspartylgly-
cosamine in urine (13), and glycoasparaginase activity was
completely absent in their leukocytes or fibroblasts. The five
Finnish normal controls were selected so that their family
history was negative with respect to aspartylglycosaminuria
and the glycoasparaginase activity in their leukocytes was
close to the upper level among controls in order to avoid
heterozygosity (14).
Cell Lines. Three fibroblast cell lines of Finnish and one
non-Finnish aspartylglycosaminuria patients (numbers
GM00568, GM02056, GM02057, and GM03560, respectively)
as well as the K562 human chronic myelogenous leukemia
cell line (GM5372) were from the National Institute of Gen-
eral Medical Sciences Human Mutant Cell Repository, Co-
riell Institute for Medical Research (Camden, NJ).
Enzyme Assays. Glycoasparaginase activity was measured
by HPLC (15).
PCR Amplification of Glycoasparaginase cDNA. An oligo-
nucleotide corresponding to glycoasparaginase cDNA resi-
dues 1074-1095 (2) (Fig. 1, amplimer B) was annealed to total
RNA isolated from peripheral blood leukocytes or cultured
fibroblasts. First-strand cDNA was then prepared by using
Moloney murine leukemia virus reverse transcriptase (Be-
thesda Research Laboratories). The second amplimer en-
compassed cDNA residues 107-128 (Fig. 1, amplimer A).
Both amplimers contained a nucleotide substitution resulting
in a Sal I site, which facilitated subsequent cloning. The
nucleotide sequences of the amplimers were A, 5'-
TGCCCCTGGTCGTCGACACTTG-3' and B, 5'-AATACA-
GATGTCGACAGTAAAG-3'. PCR was performed as de-
scribed by Kawasaki et al. (16) with minor modifications. The
reaction mixture contained 2 ,ug of total RNA, 50 pmol of
each oligonucleotide amplimer, dNTPs (each at 0.2 mM), 20
mM Tris HCl (pH 8.3), 2.5mM MgCl2, 50mM KCl, nuclease-
free bovine serum albumin at 100 Ag/ml, and 20 units of Taq
polymerase, in a total volume of 100 g1.. The mixture was
incubated 2 min at 94°C to denature the cDNA, annealed 90
sec at 55°C, and extended 2 min at 72°C. A new cycle of
amplification was started by denaturing the DNA at 94°C.
Thirty-five to 40 cycles of amplification were performed by
using a programmable heat block (Perkin-Elmer/Cetus).
Sequencing of DNA. PCR-amplified DNAs were phenol
extracted, ethanol precipitated, and digested with Sal I. The
DNA was purified by electrophoresis on a low-melting-point
agarose gel and phenol/sodium acetate extraction (17). DNA
fragments were ligated into Sal I-digested M13mpl8 or
M13mpl9 vector DNA (18). The nucleotide sequence of the
single-stranded DNA was determined by the dideoxynucle-
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FIG. 1. Structure of glycoasparaginase cDNA and PCR am-
plimers. The boxed area represents the glycoasparaginase coding
sequences; the lines represent 5' and 3' untranslated regions (from
ref. 3). The open box indicates the signal peptide, the crosshatched
box represents the heavy chain coding sequence, and the hatched
box represents the light chain coding sequence of glycoasparaginase.
The amplimers labeled A and B are shown above and below the
cDNA. The black bar labeled I indicates the region shown in Fig. 3.
The location of the EcoRI cleavage site and the three Dde I sites in
the normal glycoasparaginase cDNA are shown. The direction and
approximate location of the sequencing primers (S1-S5) are indicated
with horizontal arrows. kb, Kilobases.
otide chain-termination method according to Sanger et al.
(19) by using oligonucleotide primers based on the cDNA
sequence (see Fig. 1). The nucleotide sequences of the
primers used were S1, 5'-TACTGGAACATACAACACA-3';
S2, 5'-GTTGTAATCCATAAGAC-3'; S3, 5'-ATGGTTG-
GATCTTCTCC-3'; S4, 5'-CATTTGTAGATGTACCAG-
CAGCA-3'; and S5, 5'-CTACTAAAAGTGTGTGTG-3'. The
complete DNA sequence of a normal gene was determined
once, as well as the complete sequence ofone patient, and the
mutated area was resequenced once; all sequencing was
performed in both directions, using Sequenase (United States
Biochemical).
Mutant Screening by Allele-Specific Oligonucdeotide Hy-
bridization. The DNAs were subjected to electrophoresis on
a 1.0% gel and blotted onto a nylon membrane (Nytran,
Schleicher & Schuell). After prehybridization at 650C, oligo-
nucleotide hybridization with 32P-end-labeled oligonucleo-
tides was performed at 480C overnight, followed by washing
at gradually increased temperatures to distinguish between
perfect matches and mismatches (20). The filters were ex-
posed to x-ray film for 0.5-3 hr.
RESULTS AND DISCUSSION
Peptide Sequencing of Human Glycoasparaginase and
Nucleotide Sequence Analysis of Its cDNA. Since at least two
different cDNA clones for human glycoasparaginase have
been reported (3, 4), but the expression of an active glycoas-
paraginase enzyme from these has not been described, we
have studied the protein structure of glycoasparaginase iso-
lated from human leukocytes (2). The purified enzyme had a
specific activity of 2.2 units/mg of protein with N4-(f3-N-
acetylglucosaminyl)-L-asparagine as substrate. The 88-kDa
enzyme migrated as a single band on native PAGE. On
SDS/PAGE (under denaturing conditions) the tetrameric
enzyme was dissociated to its heavy (25-kDa) and light
(19-kDa) subunits. Our protein sequence data on the subunits
of leukocyte glycoasparaginase indicated high similarity to
that deduced from the nucleotide sequence of a cDNA clone
isolated from a human placental library based on rat liver
asparaginase amino acid sequence data (3). So oligonucleo-
tide amplimers were synthesized according to that sequence
for PCR analysis on human leukocyte mRNA. A pair of
amplimers (Fig. 1) consistently allowed amplification of an
-1-kb cDNA product (see Fig. SA, lane 2). Since both
amplimers contained a nucleotide difference from the pub-
lished sequence, resulting in generation of Sal I restriction
sites, the PCR product ofRNA of human cell line K562 could
be cloned in the Sal I site of M13, and several clones were
sequenced. The sequence from these K562 clones was similar
to the nucleotide sequence reported by Fisher et al. (3) (data
not shown). The amino acid sequence deduced from the K562
clones and the peptide sequences obtained from native gly-
coasparaginase are shown in Fig. 2. The peptide sequences
that covered about 90o of the light chain and >70% of the
heavy chain were similar to the amino acid sequence deduced
from the nucleotide sequence. All of the sequences of the
major peptides obtained from the subunits were found to be
present within the cloned sequence. In the case of the heavy
chain, the proteolytic and cyanogen bromide cleavages re-
sulted in a number of peptides that either were present in
small amounts, in mixtures of several peptides, or did not
give a signal in peptide sequencing; less sequence data were
obtained from the heavy chain than from the light chain. The
protein sequence data unambiguously demonstrated that
both our cDNA clone and that recently reported by Fisher et
al. (3) correspond to glycoasparaginase. The evidence shows
that the subunits of native, tetrameric human glycoaspara-
ginase are encoded as a single polypeptide that is posttrans-
lationally processed.
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Nucleotide and Amino Acid Sequence Analysis of cDNAs of cDNAs were
Finnish Aspartylglycosaminuria Patients. As an initial ap- We amplified
proach to identify mutations in aspartylglycosaminuria, the from anothe
same pair of amplimers that enabled the amplification of from differen
virtually the complete coding sequence of the enzyme was nuria patient
used. PCR amplification was performed on cDNA synthe- allele-specifi
sized from patient and control mRNA. The size of the synthesized
amplification product of one Finnish aspartylglycosaminuria (Fig. 5). The
patient was the same as that ofthe normal cDNA product (see all control an
Fig. SA, lane 1), excluding any major deletion in the amplified gent posthyt
region. The product was subcloned and sequenced, and two washing at 6
single-base changes, G -- A (mutation I) and G -* C (muta- signals from
tion II), were found six bases apart from one another (Fig. 3), cosaminuria l
close to the carboxyl-terminal end ofthe heavy chain (Fig. 1). the oligonucl
Mutation I created a new restriction enzyme site for Dde I, ized with all
and mutation II created a new restriction enzyme site for normal contr4
EcoRI. Mutation I results in the replacement of an arginine sample specii
residue by a glutamine residue (R161Q), and mutation II isolated from
results in the replacement of a cysteine residue by a serine glycosaminur
residue (C163S) (Fig. 4). The cDNA sequence of the light tient was dem
chain was found to be identical to that of the normal gly- seven patient
coasparaginase gene. Digestion a
Hybridization of cDNAs with Allele-Specific Oligonucleo- Endonuclease
tides. To provide additional evidence that these base substi- aspartylglyco
tutions are related to aspartylglycosaminuria and to obtain digestion of th
data regarding the frequency of these mutations, amplified addition to ar
FIG. 2. Amino acid sequence data on human
leukocyte glycoasparaginase obtained by Edman
degradation and mass spectrometry compared to
the amino acid sequence deduced from leukocyte
and placental (3) cDNA. The amino acid sequence
based on cDNA is shown on the top line using
one-letter symbols, and the residues are numbered
as in ref. 3. The peptides under the sequence are
marked according to the method used in their
generation and the technique used to sequence
them. Proteolytic and chemical cleavage methods
are designated as follows: Ch, chymotrypsin; Dn,
endoproteinase Asp-N; Ec, endoproteinase Glu-C;
Kc, endoproteinase Lys-C; T, trypsin; M, cyano-
gen bromide. The amino-terminal sequences of the
subunits were obtained by sequencing native pro-
teins. Peptides sequenced by Edman degradation
are labeled Ed and those sequenced by mass spec-
trometry are labeled MS. Unidentified residues are
designated by blank spaces. The slashes demarking
peptide lengths represent peptide-terminal amino
acids.
e analyzed with allele-specific oligonucleotides.
I glycoasparaginase cDNA for Southern analysis
r six Finnish aspartylglycosaminuria patients
it pedigrees, one non-Finnish aspartylglycosami-
t, and three non-Finnish controls. Two 21-mer
c oligonucleotides, one for each mutation, were
as shown in Fig. 4 and used for hybridization
oligonucleotide for mutation I hybridized with
id aspartylglycosaminuria DNAs after nonstrin-
bridization washing, but after more stringent
62°C [3x standard saline citrate (SSC)], only
the samples from seven Finnish aspartylgly-
patients remained (Fig. 5B1 and B2). Similarly,
leotide specific for mutation II initially hybrid-
samples, but at 56°C (3x SSC), signals from
Wls and the non-Finnish aspartylglycosaminuria
ifically disappeared (Fig. 5 Cl and C2). RNA
a blood sample of an eighth Finnish aspartyl-
ria patient was similarly analyzed, and the pa-
ionstrated to have the same two mutations as the
Ls described above (data not shown).
[f cDNAs with EcoRI and Dde I Restriction
s. The presence of the EcoRI site in the Finnish
Isaminuria patients was further demonstrated by
e PCR products with that particular enzyme. In
n EcoRI site that cleaves a 171-base-pair (bp)
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FIG. 3. DNA sequence of the region containing mutations (la-
beled I in Fig. 1). The sequence data of PCR products from a normal
individual (A) and a Finnish aspartylglycosaminuria patient (B) are
shown. Note the G-* A (mutation I) and G -* C (mutation II) changes
in the patient sample. Mutation I creates a new restriction site for
Dde I (CTCAG), and mutation II creates a new restriction site for
EcoRI (GAATTC) as indicated by the flanking brackets.
fragment from the PCR product (see Fig. 1) in both normal
and patient DNAs close to the 3' end of the light chain, all the
eight patient DNAs demonstrated a new EcoRI restriction
site that, upon EcoRI digestion, resulted in DNA fragments
of -400 bp (data not shown). This result is in accordance to
that obtained by allele-specific hybridization for mutation II
(Fig. 5 Cl and C2). In normal glycoasparaginase cDNA, Dde
I has three restriction sites (Fig. 1). Due to the new restriction
site created by mutation I, the 660-bp DNA fragment is
further cleaved to 490- and 170-bp fragments in the DNA of
the Finnish aspartylglycosaminuria patients (data not
shown). This is in accordance with the result obtained by
allele-specific hybridization for mutation I (Fig. 5 BJ and B2).
Analysis of Finnish Controls and a Non-Finnish Aspartyl-
glycosaminuria Case. To exclude an amino acid change that
is of no functional consequence for glycoasparaginase activ-
ity and would be common in the Finnish population at either
or both single-base changes, RNA from five Finnish normal,
unrelated controls with a negative family history with respect
to aspartylglycosaminuria and with high glycoasparaginase
activity in their leukocytes was analyzed as described above.
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FIG. 5. Southern analysis of normal controls and aspartylgly-
cosaminuria patients with oligonucleotides specific for mutant alleles
of glycoasparaginase. (A) Ethidium bromide-stained 1% agarose gel
with normal controls, Finnish aspartylglycosaminuria patients (lanes
1-6 and 8), and a non-Finnish patient with aspartylglycosaminuria
(lane 7). Lane M, molecular size markers (Hae III-digested 4X174RF
DNA). (BJ) Hybridization of a blot of the gel shown in A with an
oligonucleotide specific for mutation I with nonstringent posthybrid-
ization washing at 500C (3 x SSC). (B2) The blot shown in BJ after
washing under more stringent conditions (620C, 3x SSC). (Cl)
Hybridization of a blot of the gel shown in A with an oligonucleotide
for mutation II with nonstringent washing at 500C (3 x SSC). (C2) The
blot shown in Cl after washing under more stringent conditions
(560C, 3x SSC).
None of the Finnish controls demonstrated either an addi-
tional EcoRI or an additional Dde I site and thus gave the
same results as the non-Finnish controls (data not shown).
The cDNA amplified from the non-Finnish aspartylgly-
cosaminuria patient was about 100 bp (Fig. SA, lane 7) smaller
520
*
530
CAT TCA GAT TGG ClTGCr AATICCAG CCA AAT TAT TGG AGG Nonnal
H S D W L A R N C Q P N Y W R
I MutationII
CAT TCA GAT TGG CiT GCr CAG AAT I(C CAG CCA AAT TAT TGG AGG Mutant
H S D W L A Q N S Q P N Y W R
* * * *
155 160 165 169
FIG. 4. Amino acid sequence of the mutated region in Finnish aspartylglycosaminuria patients. Nucleotides are numbered above the normal
sequence; amino acid residues are numbered below the mutated sequence. The DNA sequence and the deduced protein sequence of both the
normal and the patient samples are shown. The differences between the control and the patient sequences are underlined. The allele-specific
oligonucleotide for mutation I (nucleotides 493-513) and that for mutation II (nucleotides 511-531) are indicated by lines above the mutant
sequence.
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than normal, indicating a deletion in some area of the gene.
It was similar to controls rather than to the Finnish aspar-
tylglycosaminuria patients at the EcoRI and Dde I sites (Fig.
5).
Significance of the Findings. Our extensive protein data on
human leukocyte glycoasparaginase has enabled us to con-
firm the nucleotide sequence for the cDNA of the enzyme.
We have also developed an approach to amplify almost the
entire coding region of the enzyme for cloning, sequencing,
and detection of mutations in aspartylglycosaminuria in that
region in general.
We propose that the two single-base changes described
above for the Finnish aspartylglycosaminuria patients are
point mutations typical of aspartylglycosaminuria found in
the Finnish population. Although it might have been possible
that a mutation was present in noncoding or intron sequences
in mRNA splicing, the current evidence demonstrates that
the coding region of glycoasparaginase is affected in Finnish
aspartylglycosaminuria patients. The replacement of an ar-
ginine in normal glycoasparaginase by a glutamine in the
mutant enzyme results in the substitution of a basic amino
acid for one containing an uncharged polar group. The
replacement of cysteine by serine due to mutation II may
abolish a disulfide bridge. Both amino acid changes will
obviously modify the structure of the protein profoundly, but
whether one or both are required to cause the deficiency in
activity of glycoasparaginase remains to be established. For
example, it is possible that one of the mutations corresponds
to a neutral polymorphism while the other is causative for the
gene defect. However, such polymorphism has not been
found in the alleles of the five Finnish normal individuals
studied to date. Characterization of the obvious deletion in
the non-Finnish patient (Fig. 5, lane 7) along with other
potential mutations causing the deficient activity of glycoas-
paraginase will provide important data for understanding of
the structure and function of the enzyme.
The unique genetic structure of the Finnish population due
to isolation by geographical, linguistic, and cultural barriers
is well known, but very little is known about the molecular
basis of the Finnish diseases. Gyrate atrophy of the choroid
and retina caused by deficiency of ornithine 3-aminotrans-
ferase (EC 2.6.13) is one such Finnish genetic disease.
Surprisingly, at least two different mutant alleles of ornithine
8-aminotransferase have been found in the Finnish popula-
tion (21). In this study, we have shown that in eight Finnish
aspartylglycosaminuria patients from different pedigrees two
separate point mutations are found close to the carboxyl-
terminal end of the heavy chain of glycoasparaginase. The
presence of two mutations in affected patients, but not in
normal population controls, is unusual, raising the interesting
question of the mechanism of these events. The clinical
finding that the phenotype of Finnish aspartylglycosaminuria
patients is quite uniform (8), in addition to the data presented
in this study, may indicate the presence of a single predom-
inant genotype of aspartylglycosaminuria in the Finnish
population. The findings that each of the mutations results in
the generation of a new restriction site and that these muta-
tions seem highly diagnostic for Finnish patients with aspar-
tylglycosaminuria should facilitate analysis of additional
cases and may be useful in prenatal diagnosis in families with
a history of this disease.
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